JP2023549011A - 遺伝子編集のための脂質製剤 - Google Patents

遺伝子編集のための脂質製剤 Download PDF

Info

Publication number
JP2023549011A
JP2023549011A JP2023517323A JP2023517323A JP2023549011A JP 2023549011 A JP2023549011 A JP 2023549011A JP 2023517323 A JP2023517323 A JP 2023517323A JP 2023517323 A JP2023517323 A JP 2023517323A JP 2023549011 A JP2023549011 A JP 2023549011A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
formula
nanoparticle composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549011A5 (enExample
Inventor
ラジーブ，カラントッタチル・ジー
ビスワス，スービク
マリャラ，パドマ
カシエビッチ，リサ・エヌ
ビーチ，アーロン
コレース，トーマス・ブイ
Original Assignee
ヴァーヴ・セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァーヴ・セラピューティクス，インコーポレーテッド filed Critical ヴァーヴ・セラピューティクス，インコーポレーテッド
Publication of JP2023549011A publication Critical patent/JP2023549011A/ja
Publication of JP2023549011A5 publication Critical patent/JP2023549011A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/16—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2023517323A 2020-09-15 2021-09-15 遺伝子編集のための脂質製剤 Pending JP2023549011A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063078738P 2020-09-15 2020-09-15
US63/078,738 2020-09-15
US202163220340P 2021-07-09 2021-07-09
US63/220,340 2021-07-09
PCT/US2021/050511 WO2022060871A1 (en) 2020-09-15 2021-09-15 Lipid formulations for gene editing

Publications (2)

Publication Number Publication Date
JP2023549011A true JP2023549011A (ja) 2023-11-22
JP2023549011A5 JP2023549011A5 (enExample) 2024-09-26

Family

ID=80775587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517323A Pending JP2023549011A (ja) 2020-09-15 2021-09-15 遺伝子編集のための脂質製剤

Country Status (4)

Country Link
US (3) US12024484B2 (enExample)
EP (1) EP4213882A4 (enExample)
JP (1) JP2023549011A (enExample)
WO (1) WO2022060871A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026023622A1 (ja) * 2024-07-22 2026-01-29 富士フイルム株式会社 アミノ脂質又はその塩の製造中間体としての化合物、およびそれを用いたアミノ脂質化合物の製造方法

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2613225B (en) 2020-03-04 2024-01-03 Verve Therapeutics Inc Compositions and methods for targeted RNA delivery
MX2022012683A (es) * 2020-04-09 2023-01-11 Verve Therapeutics Inc Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades.
JP2023549011A (ja) 2020-09-15 2023-11-22 ヴァーヴ・セラピューティクス，インコーポレーテッド 遺伝子編集のための脂質製剤
EP4281080A4 (en) * 2021-01-20 2025-09-24 Beam Therapeutics Inc NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT
KR20240013087A (ko) 2021-05-24 2024-01-30 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 지질 화합물 및 지질 나노입자 조성물
WO2023015223A2 (en) 2021-08-03 2023-02-09 Verve Therapeutics, Inc. Compositions and methods for targeted rna delivery
JP2024536406A (ja) * 2021-10-08 2024-10-04 スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド 脂質化合物及び脂質ナノ粒子組成物
CN114751835B (zh) * 2022-03-15 2024-09-17 大连民族大学 一类含有多个酯键可电离叔胺脂质及其合成方法和应用
CN116354836A (zh) * 2022-03-25 2023-06-30 深圳市新合生物医疗科技有限公司 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
CN114890907B (zh) * 2022-03-31 2023-10-31 荣灿生物医药技术(上海)有限公司 一种阳离子脂质化合物及其制备方法和应用
TW202404568A (zh) * 2022-04-07 2024-02-01 美商Ｒｎａ免疫公司 用於藥物遞送之化合物及組合物
CN117003808A (zh) * 2022-04-28 2023-11-07 北京科兴中维生物技术有限公司 一种阳离子脂质化合物及其制备方法和用途
CN114874104B (zh) * 2022-04-29 2024-11-29 湖北英纳氏生物科技有限公司 阳离子脂质体SM-102及Lipid5的制备方法
WO2023215790A1 (en) * 2022-05-03 2023-11-09 The Board Of Regents Of The University Of Texas System Co-delivery of inhibitory nucleic acids and genome editors for tumor therapy
WO2023230601A1 (en) 2022-05-27 2023-11-30 Beam Therapeutics Inc. Identification of nanoparticles for preferential tissue or cell targeting
GB2634837A (en) 2022-06-07 2025-04-23 Scribe Therapeutics Inc Compositions and methods for the targeting of PCSK9
CN115286674A (zh) * 2022-06-13 2022-11-04 湖北英纳氏生物科技有限公司 一种阳离子脂质体及其制备方法
CN116969850A (zh) * 2022-06-14 2023-10-31 苏州科锐迈德生物医药科技有限公司 碳酸酯-羧酸酯型脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
WO2024012272A1 (zh) * 2022-07-11 2024-01-18 传信生物医药(苏州)有限公司 脂质化合物及其应用
EP4559896A4 (en) * 2022-07-19 2025-10-22 Univ Hokkaido Nat Univ Corp PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE
CN117800859A (zh) * 2022-09-26 2024-04-02 苏州科锐迈德生物医药科技有限公司 具有戊二酸骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN115504945B (zh) * 2022-10-09 2025-09-02 南京吉迈生物技术有限公司 可电离的含杂环脂质分子及其在制备脂质纳米粒的应用
CN115417779B (zh) * 2022-11-03 2023-06-16 北京华芢生物技术有限公司 可离子化的阳离子脂c6-a1及由其组成的纳米脂质体颗粒
CN115417780B (zh) * 2022-11-04 2023-06-20 北京华芢生物技术有限公司 可离子化的阳离子脂c5-a2及由其组成的纳米脂质体颗粒
WO2024199282A1 (zh) * 2023-03-28 2024-10-03 苏州艾博生物科技有限公司 脂质化合物和脂质纳米颗粒组合物
CN120957730A (zh) * 2023-03-29 2025-11-14 国立大学法人东北大学 核酸封装脂质纳米粒子的制造方法
JPWO2024248146A1 (enExample) * 2023-05-31 2024-12-05
CN117024323A (zh) * 2023-07-21 2023-11-10 中国科学院基础医学与肿瘤研究所(筹) 一种可降解、可电离的阳离子脂材及其应用
AU2024325364A1 (en) * 2023-08-16 2026-03-26 Beam Therapeutics Inc. Ionizable lipids with branched head groups
CN117986153A (zh) * 2023-09-07 2024-05-07 晟迪生物医药(苏州)有限公司 一种可电离阳离子脂质化合物及其制备方法和应用
WO2025059599A1 (en) * 2023-09-13 2025-03-20 Tessera Therapeutics, Inc. Lipid nanoparticles for delivery of therapeutic payloads to cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095340A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP2017523965A (ja) * 2014-07-16 2017-08-24 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
JP2019516351A (ja) * 2016-03-30 2019-06-20 インテリア セラピューティクス，インコーポレイテッド Ｃｒｉｓｐｒ／ｃａｓ構成成分のための脂質ナノ粒子製剤
JP2020500539A (ja) * 2016-12-09 2020-01-16 サンガモ セラピューティクス， インコーポレイテッド 標的特異的ヌクレアーゼの送達
WO2020219876A1 (en) * 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
DE102004054730A1 (de) 2004-03-28 2006-05-11 Novosom Ag Serumstabile amphotere Liposomen
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
US20070087045A1 (en) 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
EP1989179B1 (en) * 2006-02-15 2011-01-26 Ge Healthcare As Contrast agents
FR2928925B1 (fr) 2008-03-19 2011-01-07 Centre Nat Rech Scient Complexes de bore ou d'aluminium, et leurs utilisations.
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US8883211B2 (en) 2008-07-10 2014-11-11 Serina Therapeutics, Inc. Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
CN101724210B (zh) 2009-12-22 2012-05-23 浙江科技学院 用于加工pvc透明片材的稳定剂及其制备方法和应用
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US20120178858A1 (en) 2011-01-10 2012-07-12 Andrew Julian Wnuk Isosorbide-Plasticized Starch And Uses Thereof
US8691750B2 (en) * 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
CN102617364B (zh) 2012-03-15 2014-04-23 南京工业大学 羟甲基二胺类化合物及其制备方法与应用
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2014008334A1 (en) 2012-07-06 2014-01-09 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
WO2014089239A1 (en) 2012-12-07 2014-06-12 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
CN107879960B (zh) 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
US10426737B2 (en) * 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
RU2698697C2 (ru) 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
EP3258952A4 (en) 2015-02-04 2018-12-05 Pacific Biosciences Of California, Inc. Multimeric protected fluorescent reagents
EP3275448B1 (en) 2015-03-24 2025-10-29 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticles
WO2016197133A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics, Inc. Delivering crispr therapeutics with lipid nanoparticles
JP6768011B2 (ja) 2015-06-23 2020-10-14 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｃｄ１２３抗体との抗体薬物複合体
US20180200186A1 (en) 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
US11231415B2 (en) * 2016-05-12 2022-01-25 Z Biotech Llc Multivalent glycan microarray platform
WO2017222016A1 (ja) * 2016-06-24 2017-12-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 カチオン性脂質
WO2018062413A1 (ja) 2016-09-28 2018-04-05 協和発酵キリン株式会社 核酸含有脂質ナノ粒子
WO2018119514A1 (en) 2016-12-28 2018-07-05 Precision Nanosystems Inc. Compositions for transfecting resistant cell types
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP4186888B1 (en) 2017-03-15 2025-11-26 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
DK3607069T3 (da) 2017-04-05 2022-11-21 Silence Therapeutics Gmbh Produkter og sammensætninger
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
BR112019025104A2 (pt) * 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição
WO2019027055A1 (ja) 2017-08-04 2019-02-07 協和発酵キリン株式会社 核酸含有脂質ナノ粒子
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
US20230140670A1 (en) 2017-09-29 2023-05-04 Intellia Therapeutics, Inc. Formulations
KR102832035B1 (ko) * 2017-09-29 2025-07-09 인텔리아 테라퓨틱스, 인크. 지질 나노파티클을 이용한 mRNA 전달의 체외 방법
EP3733647B1 (en) * 2017-12-27 2022-06-15 Eisai R&D Management Co., Ltd. Cationic lipid
IL294318A (en) 2020-01-09 2022-08-01 Guide Therapeutics Llc Nanomaterials
CA3181340A1 (en) 2020-04-28 2021-11-04 Intellia Therapeutics, Inc. Methods of in vitro cell delivery
EP4153223A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
IL298362A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
WO2021243301A2 (en) 2020-05-29 2021-12-02 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
KR20230029685A (ko) 2020-05-29 2023-03-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 Trem 조성물 및 이에 관련된 방법
JP2023549011A (ja) 2020-09-15 2023-11-22 ヴァーヴ・セラピューティクス，インコーポレーテッド 遺伝子編集のための脂質製剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095340A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP2017523965A (ja) * 2014-07-16 2017-08-24 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
JP2019516351A (ja) * 2016-03-30 2019-06-20 インテリア セラピューティクス，インコーポレイテッド Ｃｒｉｓｐｒ／ｃａｓ構成成分のための脂質ナノ粒子製剤
JP2020500539A (ja) * 2016-12-09 2020-01-16 サンガモ セラピューティクス， インコーポレイテッド 標的特異的ヌクレアーゼの送達
WO2020219876A1 (en) * 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026023622A1 (ja) * 2024-07-22 2026-01-29 富士フイルム株式会社 アミノ脂質又はその塩の製造中間体としての化合物、およびそれを用いたアミノ脂質化合物の製造方法

Also Published As

Publication number Publication date
US20240010609A1 (en) 2024-01-11
EP4213882A4 (en) 2025-02-26
US20240368071A1 (en) 2024-11-07
US12410122B2 (en) 2025-09-09
EP4213882A1 (en) 2023-07-26
WO2022060871A1 (en) 2022-03-24
US12024484B2 (en) 2024-07-02
US20250340506A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
JP2023549011A (ja) 遺伝子編集のための脂質製剤
JP7485659B2 (ja) イオン化可能なアミン脂質
US12268753B2 (en) Nanomaterials comprising a biodegradable feature
TWI594767B (zh) 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
CN116916904A (zh) 用于基因编辑的脂质制剂
AU2023202793B2 (en) Fusogenic compounds for delivery of biologically active molecules
EP2350296A1 (en) Branched cationic lipids for nucleic acids delivery system
CN104159615A (zh) 含有阳离子性脂质的组合的脂质纳米粒子
US20250049729A1 (en) Poegma-based lipid nanoparticles
EP3153172A1 (en) Ckap5-gene-silencing rnai pharmaceutical composition
EP3395797B1 (en) Compounds as cationic lipids
WO2025264883A1 (en) Anionic lipid nanoparticles for nucleic acid delivery
WO2025072150A1 (en) Zwitterionic lipid nanoparticle compositions, and methods of use
WO2025063214A1 (ja) 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法
HK40053394A (en) Ionizable amine lipids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260302